- Report
- January 2026
- 193 Pages
Global
From €3432EUR$3,939USD£2,981GBP
- Report
- June 2025
- 135 Pages
Global
From €3485EUR$3,999USD£3,026GBP
- Report
- January 2026
- 180 Pages
Global
From €3432EUR$3,939USD£2,981GBP
- Report
- September 2025
- 250 Pages
Global
From €3912EUR$4,490USD£3,397GBP
- Report
- January 2026
- 279 Pages
Global
From €5097EUR$5,850USD£4,427GBP
- Report
- November 2025
- 87 Pages
Global
From €3500EUR$4,303USD£3,146GBP
- Report
- May 2025
- 483 Pages
Global
From €5185EUR$6,158USD£4,350GBP
- Report
- February 2025
- 190 Pages
Global
From €4182EUR$4,799USD£3,631GBP
- Report
- March 2025
Global
From €4270EUR$4,900USD£3,708GBP
- Report
- February 2025
- 150 Pages
Global
From €5185EUR$5,950USD£4,502GBP
- Report
- November 2025
- 150 Pages
Global
From €5185EUR$5,950USD£4,502GBP
- Report
- June 2025
- 150 Pages
Global
From €5185EUR$5,950USD£4,502GBP
- Report
- February 2025
- 150 Pages
Global
From €3485EUR$3,999USD£3,026GBP
- Report
- January 2026
- 180 Pages
Global
From €3432EUR$3,939USD£2,981GBP
- Report
- August 2025
- 197 Pages
Global
From €3432EUR$3,939USD£2,981GBP
- Report
- September 2025
- 250 Pages
Global
From €3912EUR$4,490USD£3,397GBP
- Report
- January 2026
- 181 Pages
Global
From €3921EUR$4,500USD£3,405GBP
- Report
- March 2025
- 184 Pages
Global
From €3921EUR$4,500USD£3,405GBP
- Report
- December 2025
- 250 Pages
Global
From €3912EUR$4,490USD£3,397GBP
- Report
- September 2025
- 250 Pages
Global
From €3912EUR$4,490USD£3,397GBP

RNAi therapy is a type of biotechnology that uses small pieces of RNA to target and silence specific genes. This technology has been used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. RNAi therapy works by introducing small interfering RNAs (siRNAs) into cells, which then bind to and degrade messenger RNAs (mRNAs) that encode for specific proteins. This process can be used to reduce the expression of disease-causing genes, or to activate beneficial genes.
RNAi therapy has the potential to revolutionize the treatment of many diseases, as it is a more precise and targeted approach than traditional drug therapies. It is also less toxic and has fewer side effects. However, the development of RNAi therapies is still in its early stages, and there are many challenges that need to be addressed before they can be widely used in clinical settings.
Some companies in the RNAi therapy market include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Moderna Therapeutics. Show Less Read more